2268:HKEXWuXi XDC Cayman, Inc. Analysis
Data as of 2026-03-14 - not real-time
HK$54.10
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
WuXi XDC is trading at HK$54.1, well below the analyst median target of HK$84.8, implying roughly a 57% upside. The company delivered 62% YoY revenue growth, an operating margin of 28%, ROE around 20%, and a forward PE of 27.6, indicating strong earnings momentum despite a trailing PE of 46.6.
Technical indicators place the price beneath the 20‑day (≈61) and 50‑day (≈64) SMAs, with RSI at 35 and a bearish MACD, suggesting short‑term pressure but also an oversold condition near the identified support of HK$53.55. Volume is increasing, offering liquidity for a potential bounce.
The newly announced strategic collaboration with Earendil Labs on the WuXiTecan‑2 payload‑linker platform adds a credible growth catalyst in the fast‑growing ADC market. Coupled with a low beta (≈0.35) and a strong cash position versus debt, the fundamentals support a medium‑term rally, while the absence of a dividend means returns rely on capital appreciation.
Technical indicators place the price beneath the 20‑day (≈61) and 50‑day (≈64) SMAs, with RSI at 35 and a bearish MACD, suggesting short‑term pressure but also an oversold condition near the identified support of HK$53.55. Volume is increasing, offering liquidity for a potential bounce.
The newly announced strategic collaboration with Earendil Labs on the WuXiTecan‑2 payload‑linker platform adds a credible growth catalyst in the fast‑growing ADC market. Coupled with a low beta (≈0.35) and a strong cash position versus debt, the fundamentals support a medium‑term rally, while the absence of a dividend means returns rely on capital appreciation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support at HK$53.55
- Oversold RSI suggesting potential bounce
- Increasing volume providing liquidity
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong 62% revenue growth and high operating margins
- Strategic partnership with Earendil Labs expanding ADC pipeline
- Significant upside to analyst target price (~57%)
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Sustainable cash generation and low systematic risk (beta 0.35)
- Long‑term tailwinds in bioconjugate and ADC markets
- Potential regulatory and China‑specific execution risks
Key Metrics & Analysis
Financial Health
Revenue Growth62.20%
Profit Margin26.08%
P/E Ratio46.6
ROE19.76%
ROA9.04%
Debt/Equity13.96
P/B Ratio7.7
Op. Cash FlowHK$1.5B
Free Cash FlowHK$-332979488
Industry P/E26.2
Technical Analysis
TrendNeutral
RSI35.4
SupportHK$53.55
ResistanceHK$68.10
MA 20HK$61.01
MA 50HK$64.12
MA 200HK$61.18
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair ValueHK$34.80
Target PriceHK$85.42
Upside/Downside57.88%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.35
Volatility52.70%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.